Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

Guidelines for the successful generation of protein-ligand complex crystals.

Müller I.

Acta Crystallogr D Struct Biol. 2017 Feb 1;73(Pt 2):79-92. doi: 10.1107/S2059798316020271. Epub 2017 Feb 1.

2.

Dynamics-Driven Allostery in Protein Kinases.

Kornev AP, Taylor SS.

Trends Biochem Sci. 2015 Nov;40(11):628-47. doi: 10.1016/j.tibs.2015.09.002. Epub 2015 Oct 21. Review.

3.

Small-Molecule Allosteric Modulators of the Protein Kinase PDK1 from Structure-Based Docking.

Rettenmaier TJ, Fan H, Karpiak J, Doak A, Sali A, Shoichet BK, Wells JA.

J Med Chem. 2015 Oct 22;58(20):8285-91. doi: 10.1021/acs.jmedchem.5b01216. Epub 2015 Oct 12.

4.

Discovery of a Potent Allosteric Kinase Modulator by Combining Computational and Synthetic Methods.

Kroon E, Schulze JO, Süß E, Camacho CJ, Biondi RM, Dömling A.

Angew Chem Int Ed Engl. 2015 Nov 16;54(47):13933-6. doi: 10.1002/anie.201506310. Epub 2015 Sep 4.

5.

PS48 can replace bovine serum albumin in pig embryo culture medium, and improve in vitro embryo development by phosphorylating AKT.

Spate LD, Brown A, Redel BK, Whitworth KM, Prather RS.

Mol Reprod Dev. 2015 Apr;82(4):315-20. doi: 10.1002/mrd.22474. Epub 2015 Mar 16.

6.

Ten things you should know about protein kinases: IUPHAR Review 14.

Fabbro D, Cowan-Jacob SW, Moebitz H.

Br J Pharmacol. 2015 Jun;172(11):2675-700. doi: 10.1111/bph.13096. Epub 2015 Mar 24. Review.

7.

A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.

Rettenmaier TJ, Sadowsky JD, Thomsen ND, Chen SC, Doak AK, Arkin MR, Wells JA.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18590-5. doi: 10.1073/pnas.1415365112. Epub 2014 Dec 17.

8.

PDK1 inhibitors.

Barile E, De SK, Pellecchia M.

Pharm Pat Anal. 2012 May;1(2):145-63. doi: 10.4155/ppa.12.17. Review.

9.

A neo-substrate that amplifies catalytic activity of parkinson's-disease-related kinase PINK1.

Hertz NT, Berthet A, Sos ML, Thorn KS, Burlingame AL, Nakamura K, Shokat KM.

Cell. 2013 Aug 15;154(4):737-47. doi: 10.1016/j.cell.2013.07.030.

10.

Comparing Conformational Ensembles Using the Kullback-Leibler Divergence Expansion.

McClendon CL, Hua L, Barreiro A, Jacobson MP.

J Chem Theory Comput. 2012 Jul 12;8(6):2115-2126. Epub 2012 Apr 13.

11.

Exploiting protein flexibility to predict the location of allosteric sites.

Panjkovich A, Daura X.

BMC Bioinformatics. 2012 Oct 25;13:273. doi: 10.1186/1471-2105-13-273.

12.

Regulation of protein kinase C-related protein kinase 2 (PRK2) by an intermolecular PRK2-PRK2 interaction mediated by Its N-terminal domain.

Bauer AF, Sonzogni S, Meyer L, Zeuzem S, Piiper A, Biondi RM, Neimanis S.

J Biol Chem. 2012 Jun 8;287(24):20590-602. doi: 10.1074/jbc.M111.327437. Epub 2012 Apr 16.

13.

Biophysical and mechanistic insights into novel allosteric inhibitor of spleen tyrosine kinase.

Hall J, Aulabaugh A, Rajamohan F, Liu S, Kaila N, Wan ZK, Ryan M, Magyar R, Qiu X.

J Biol Chem. 2012 Mar 2;287(10):7717-27. doi: 10.1074/jbc.M111.311993. Epub 2012 Jan 4.

14.

Regulation of the catalytic activity of the EGF receptor.

Endres NF, Engel K, Das R, Kovacs E, Kuriyan J.

Curr Opin Struct Biol. 2011 Dec;21(6):777-84. doi: 10.1016/j.sbi.2011.07.007. Epub 2011 Aug 23. Review.

15.

Inhibition of HIV-1 Tat-mediated transcription by a coumarin derivative, BPRHIV001, through the Akt pathway.

Lin PH, Ke YY, Su CT, Shiao HY, Hsieh HP, Chao YK, Lee CN, Kao CL, Chao YS, Chang SY.

J Virol. 2011 Sep;85(17):9114-26. doi: 10.1128/JVI.00175-11. Epub 2011 Jun 22.

16.

Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms.

Jura N, Zhang X, Endres NF, Seeliger MA, Schindler T, Kuriyan J.

Mol Cell. 2011 Apr 8;42(1):9-22. doi: 10.1016/j.molcel.2011.03.004. Review.

17.

Turning a protein kinase on or off from a single allosteric site via disulfide trapping.

Sadowsky JD, Burlingame MA, Wolan DW, McClendon CL, Jacobson MP, Wells JA.

Proc Natl Acad Sci U S A. 2011 Apr 12;108(15):6056-61. doi: 10.1073/pnas.1102376108. Epub 2011 Mar 23.

18.

Reprogramming of human primary somatic cells by OCT4 and chemical compounds.

Zhu S, Li W, Zhou H, Wei W, Ambasudhan R, Lin T, Kim J, Zhang K, Ding S.

Cell Stem Cell. 2010 Dec 3;7(6):651-5. doi: 10.1016/j.stem.2010.11.015. No abstract available.

19.

Allosteric regulation of glycogen synthase kinase 3β: a theoretical study.

Buch I, Fishelovitch D, London N, Raveh B, Wolfson HJ, Nussinov R.

Biochemistry. 2010 Dec 28;49(51):10890-901. doi: 10.1021/bi100822q. Epub 2010 Dec 3.

20.

Structural and dynamic determinants of ligand binding and regulation of cyclin-dependent kinase 5 by pathological activator p25 and inhibitory peptide CIP.

Cardone A, Hassan SA, Albers RW, Sriram RD, Pant HC.

J Mol Biol. 2010 Aug 20;401(3):478-92. doi: 10.1016/j.jmb.2010.06.040. Epub 2010 Jun 25.

Supplemental Content

Support Center